Multiple Sclerosis
Conditions
Keywords
wearing off, ocrelizumab, ublituximab
Brief summary
The proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon.
Interventions
DRUGUblituximab
Ublituzimab will be administered via IV infusion as specified throughout the study period.
DRUGOcrelizumab
Ocrelizumab will be administered via IV infusion as specified throughout the treatment period.
Sponsors
Johns Hopkins University
TG Therapeutics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patients with relapsing forms of MS. * Age between 18 and 65 years old (inclusive). * On treatment with standard interval ocrelizumab for at least one year. * Eligible and willing to continue treatment with ocrelizumab or ublituximab. * The presence of wearing off phenomena, defined as either worsening in any Neuro-QoL sleep disturbance, fatigue, depression, upper and lower extremity scores (moving from a lower category of symptom severity to a higher category, based on previously defined cutoff scores), a worsening of Neuro-QoL score of 10 points (which equals 1 SD) or more in any domain between a 1-2 month post-infusion assessment (after one ocrelizumab infusion) and a 1-2 month pre-infusion assessment (before the next scheduled infusion).
Exclusion criteria
* Prior therapy: Has ever received any of the following: * B-cell targeted therapies: rituximab, ofatumumab, ublituximab or other anti-CD20 agents besides ocrelizumab. * Prior use of cladribine, alemtuzumab, mitoxantrone, cyclophosphamide or HSCT. * Lymphopenia: a lymphocyte count \<500/ millimeter (mm)\^3. Historical labs may be used if the collection date is 6 months or less prior to deeming eligible. * Neutrophils \<1.5X10E9/L. Historical labs may be used if the collection date is 6 months or less prior to deeming eligible. * Clinically unstable medical or psychiatric disorder. * Substance abuse: has evidence of current drug or alcohol abuse or dependence. * 365 Day prior therapy: has received a biologic investigational agent other than B-cell targeted therapy \[e.g., anti CD40L antibody\]. * Malignancy: has a history of malignancy in the past 5 years except for adequately treated cancers of the skin (basal or squamous cell) or carcinoma in situ of the uterine cervix. * Have a history of a primary immunodeficiency. * Have a significant IgG deficiency (IgG level \< 400 mg/dL). * Have an IgA deficiency (IgA level \< 10 mg/dL). * Infection history: * Currently on any suppressive therapy for chronic infection (such as tuberculosis, pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster, and atypical mycobacteria). * Hospitalization for treatment of infection within 60 days of Screening. * Use of parenteral (IV or IM) antibiotics (anti-bacterial, antiviral, anti-fungal, or anti-parasitic agents) within 60 days of Screening. * Other disease/conditions: has any of the following: a) clinical evidence of significant unstable or uncontrolled acute or chronic diseases (i.e., cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, neurological, malignancy or infectious diseases) which, in the opinion of the investigator, could confound the results of the study or put the subject at undue risk. * Hepatitis status: * Serologic evidence of current or past Hepatitis B (HB) infection based on the results of testing for HBsAg and HBcAb as follows: Patients positive for HBsAg or HBcAb are excluded. * A positive test for Hepatitis C antibody * HIV: known to have a historically positive HIV test or tests positive at screening for HIV. * Laboratory abnormalities: An abnormal laboratory assessment is made, which is judged clinically significant by the investigator. * Drug Sensitivity: has a history of sensitivity to any of the study medications. * Any contraindication to undergoing MRI. * TB: tests positive at screening for tuberculosis. * Impaired decision-making capacity or impaired ability to provide informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Patients with Wearing-Off | From month 1 up to 11 months | The proportion of patients with the wearing-off phenomenon (as defined below). Wearing off is defined as either worsening in any Neuro-QoL (Quality of Life in Neurological Disorders) fatigue, depression, upper and lower extremity scores (moving from a lower category of symptom severity to a higher category, based on previously defined cutoff scores) or 0.5-point worsening in average SymptoMScreen score. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The Frequency and Severity of Wearing-Off Events as assessed by the number of Neuro-QoL or SymptoMScreen events | From month 1 up to 11 months | The number of Neuro-QoL (Quality of Life in Neurological Disorders) or SymptoMScreen events (as defined below) per patient per infusion cycle that qualifies as a marker of wearing off. Wearing off events are defined as either worsening in any Neuro-QoL fatigue, depression, upper and lower extremity scores (moving from a lower category of symptom severity to a higher category, based on previously defined cutoff scores) or 0.5-point worsening in average SymptoMScreen score. |
Countries
United States
Contacts
CONTACTZiyun Research Program Coordinator
PRINCIPAL_INVESTIGATORShiv Saidha, MD
Johns Hopkins University
Outcome results
None listed